BPC-157 Australia: Complete Research Guide
For laboratory research use only. Not for human use. Research use only.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It has been extensively studied in preclinical models for its apparent role in tissue repair, angiogenesis, and gastrointestinal health. This guide provides a comprehensive research overview for Australian researchers sourcing research-grade BPC-157.
What is BPC-157?
BPC-157 is a 15-amino acid peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) first isolated from human gastric juice. It is classified as a stable gastric pentadecapeptide and has been the subject of over 100 preclinical studies examining its biological activity in rodent models.
Unlike many peptides, BPC-157 demonstrates oral and systemic activity in preclinical models, which has made it a subject of significant research interest. It is not currently approved by the TGA as a therapeutic agent and is available in Australia for laboratory research use only.
Preclinical Research Findings
Preclinical studies have examined BPC-157 across a range of biological systems. In rodent models, researchers have observed apparent effects on tendon-to-bone healing, muscle repair following crush injuries, and gastrointestinal mucosal integrity. A 2019 study published in the Journal of Physiology and Pharmacology examined BPC-157's apparent role in modulating nitric oxide synthesis pathways in rodent models.
Research has also examined BPC-157's interaction with the dopaminergic and serotonergic systems in preclinical models. Studies have noted apparent modulation of neurotransmitter activity, which has prompted further investigation into its potential neuroprotective properties in animal models.
Mechanism of Action
The precise mechanism of action for BPC-157 in preclinical models is not fully characterised. Current research suggests it may interact with the nitric oxide (NO) system, upregulate growth hormone receptors at the local tissue level, and modulate the expression of genes involved in angiogenesis and tissue remodelling.
Researchers have noted apparent activation of the FAK-paxillin pathway in tendon fibroblast models, which may contribute to the observed tissue repair effects in preclinical studies. This pathway is involved in cell migration and adhesion, both of which are critical processes in wound healing.
Research-Grade Supply in Australia
PeptideIQ supplies research-grade BPC-157 in Australia, manufactured to ≥98% purity as verified by third-party HPLC testing. Each batch is accompanied by a Certificate of Analysis (CoA) confirming purity, identity, and absence of contaminants.
BPC-157 is available in lyophilised powder form, which provides maximum stability during storage and shipping. All products are shipped with appropriate cold chain packaging to maintain integrity during transit across Australia.
Frequently Asked Questions
Is BPC-157 legal in Australia?
BPC-157 is not listed on the ARTG as an approved therapeutic good. It is available in Australia for laboratory research use only, in compliance with the Therapeutic Goods Act 1989. It is not approved for human use or consumption.
What purity is PeptideIQ's BPC-157?
PeptideIQ supplies BPC-157 at ≥98% purity as verified by third-party HPLC testing. Each batch includes a Certificate of Analysis.
How should BPC-157 be stored for research?
Lyophilised BPC-157 should be stored at -20°C in a sealed container away from light and moisture. Once reconstituted with bacteriostatic water, it should be stored at 4°C and used within 30 days.
Disclaimer: All products supplied by PeptideIQ are for laboratory research use only. They are not approved for human use, consumption, or therapeutic application. PeptideIQ complies with all applicable Australian regulations including the Therapeutic Goods Act 1989.